Genmab A (GMAB) Retained Earnings (2019 - 2026)

Genmab A has reported Retained Earnings for 6 years, with the latest figure at $4.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings rose 15.63% year-over-year to $4.1 billion; the trailing twelve-month figure through Mar 2026 stood at $4.1 billion (up 15.63% YoY), and the FY2025 full-year result was $4.1 billion, up 1913.27% from the prior year.
• Retained Earnings for Q1 2026 stood at $4.1 billion, roughly flat from $4.1 billion in the prior quarter.
• The five-year high for Retained Earnings was $4.1 billion in Q4 2025, with the low at -$226.0 million in Q4 2024.
• Historically, Retained Earnings has averaged $3.1 billion across 4 years, with a median of $3.6 billion in 2025.
• Annual changes were most pronounced in 2024 — Retained Earnings sank 108.26% — and 2025, when it jumped 1913.27%.
• Genmab A's Retained Earnings stood at $2.7 billion in 2023, then slumped by 108.26% to -$226.0 million in 2024, then jumped by 1913.27% to $4.1 billion in 2025, then dropped by 0.2% to $4.1 billion in 2026.
• The last three Retained Earnings figures came in at $4.1 billion (Q1 2026), $4.1 billion (Q4 2025), and $4.0 billion (Q3 2025), per Business Quant data.